BridgeBio Pharma (BBIO) Research & Development (2018 - 2026)

BridgeBio Pharma has disclosed Research & Development across 9 years of filings, most recently posting $126.6 million for Q1 2026.

• Research & Development for Q1 2026 came in at $126.6 million, up 13.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $467.2 million (down 2.05% YoY), and the FY2025 annual result was $452.0 million, down 10.76% from the prior year.
• Research & Development came in at $126.6 million for Q1 2026 at BridgeBio Pharma, up from $116.4 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $141.0 million in Q1 2024 to a low of $90.9 million in Q4 2022.
• The 5-year median for Research & Development is $112.9 million (2025), against an average of $114.1 million.
• Across the five-year window, Research & Development declined 25.61% in 2022 and jumped 51.81% in 2024, its largest moves.
• BridgeBio Pharma's Research & Development stood at $90.9 million in 2022, then soared by 43.26% to $130.2 million in 2023, then rose by 0.1% to $130.4 million in 2024, then declined by 10.69% to $116.4 million in 2025, then advanced by 8.78% to $126.6 million in 2026.
• The last three Research & Development figures came in at $126.6 million (Q1 2026), $116.4 million (Q4 2025), and $112.9 million (Q3 2025), per Business Quant data.